公开(公告)号：US20220143231A1

公开(公告)日：2022-05-12

申请号：US17522144

申请日：2021-11-09

Applicant: Janssen Biotech, Inc.

Inventor： Rhys Salter ,  Vadim Y. Dudkin ,  Fengbin Song ,  Wei Zhang ,  Shalom Goldberg ,  John Keith

IPC: A61K51/10 ,  A61K47/55 ,  A61K51/04 ,  A61K47/68 ,  A61K47/54

Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.

公开(公告)号：US20240238461A1

公开(公告)日：2024-07-18

申请号：US18516304

申请日：2023-11-21

Applicant: Janssen Biotech, Inc.

Inventor： Rhys Salter ,  Vadim Y. Dudkin ,  Fengbin Song ,  Wei Zhang ,  Shalom Goldberg ,  John Keith

IPC: A61K51/10 ,  A61K47/54 ,  A61K47/55 ,  A61K47/68 ,  A61K51/04

CPC classification number: A61K51/1096 ,  A61K47/545 ,  A61K47/55 ,  A61K47/6803 ,  A61K51/0497

Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.

公开(公告)号：US11576986B2

公开(公告)日：2023-02-14

申请号：US16869771

申请日：2020-05-08

Applicant: Janssen Biotech, Inc.

Inventor： Rhys Salter ,  Vadim Dudkin ,  Fengbin Song ,  Wei Zhang ,  Shalom Goldberg ,  John Keith

IPC: A61K51/02 ,  A61K51/04 ,  A61K51/10

Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.